Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Bromelain, a concentrate of proteolytic enzymes from the pineapple plant, is used in medicine. It is approved in the European Union for the debridement (removal of eschar, that is dead and damaged tissue) of severe burn wounds under the brand name Nexobrid. It was developed by MediWound.
Applications & Regions
Explore the main themes, entities and connections around Bromelain (pharmacology). Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
bromelain nexobrid enzymes gel burns studies approved concentrate proteolytic pineapple medicine european effects medical 19 drug status anacaulase-bcdb debridement eschar
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Bromelain (pharmacology) | AHFS/Drugs.com | UK Drug Information | 1.00 | infobox |
| Bromelain (pharmacology) | ATC code | D03BA03 (WHO) | 1.00 | infobox |
| Bromelain (pharmacology) | CAS Number | 37189-34-7 | 1.00 | infobox |
| Bromelain (pharmacology) | ChemSpider | none | 1.00 | infobox |
| Bromelain (pharmacology) | CompTox Dashboard (EPA) | DTXSID901010881 | 1.00 | infobox |
| Bromelain (pharmacology) | DrugBank | DB12249 | 1.00 | infobox |
| Bromelain (pharmacology) | ECHA InfoCard | 100.029.599 | 1.00 | infobox |
| Bromelain (pharmacology) | Elimination half-life | 11.7±3.5 (8.5–19.9) hrs | 1.00 | infobox |
| Bromelain (pharmacology) | KEGG | D03162 | 1.00 | infobox |
| Bromelain (pharmacology) | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Bromelain (pharmacology) | Legal status | US: ℞-only | 1.00 | infobox |
| Bromelain (pharmacology) | Legal status | EU: Rx-only | 1.00 | infobox |
| Bromelain (pharmacology) | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Bromelain (pharmacology) | License data | US DailyMed: Anacaulase | 1.00 | infobox |
| Bromelain (pharmacology) | Other names | Anacaulase-bcdb | 1.00 | infobox |
| Bromelain (pharmacology) | Protein binding | ~50% (bromelain) | 1.00 | infobox |
| Bromelain (pharmacology) | Routes of administration | Topical | 1.00 | infobox |
| Bromelain (pharmacology) | Trade names | Nexobrid | 1.00 | infobox |
| Bromelain (pharmacology) | UNII | ZLM4P8929R | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.